Clinical observation on the use of nalbuphine or alfentanil for anesthesia in elderly patients undergoing ERCP

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034707

Enrollment

Unknown

Registered

2020-07-15

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ERCP

Interventions

Group N:Nalbuphine

Group A:Alfentanil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients scheduled to undergo therapeutic ERCP under general intravenous anesthesia; 2. Aged above 60 years; 3. ASA grades II and III 4.Sign informed consent.

Exclusion criteria

Exclusion criteria: 1.Serious cardiovascular disease; 2.Severe bradycardia; 3.Severe neurological disease; 4.Difficult airway and severe respiratory disease; 5.Establish or suspect a long or abusive history of psychotropic substances, drug addiction, alcohol abuse; 6.Allergic to narcotic sedatives and analgesics; 7.Poor communication and coordination.

Design outcomes

Primary

Measure	Time frame
Basic vital signs at each observation time point;analgesic effect;Incidence of adverse events;	—

Countries

China

Contacts

Public ContactJin-Gui Gao

Second Hospital of Hebei Medical University

gaojingui@126.com+86 15803210586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026